Verrica Pharmaceuticals Inc.
VRCA
$6.11
-$0.04-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 76.64% | 69.39% | 44.09% | 18.27% | -14.31% |
| Total Depreciation and Amortization | -38.46% | -31.55% | -8.99% | 16.74% | 51.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.63% | -37.17% | -53.62% | -41.39% | -30.28% |
| Change in Net Operating Assets | -408.44% | -212.44% | -2,831.65% | -100.72% | -79.44% |
| Cash from Operations | 71.07% | 50.99% | 27.86% | 0.51% | -57.94% |
| Capital Expenditure | -- | 100.00% | 94.72% | 92.31% | 92.54% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 103.15% | 97.36% | 94.59% | 94.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5,116.67% | -2,093.72% | -2,372.75% | -2,595.53% | -3,917.39% |
| Issuance of Common Stock | 17.37% | 27,498.70% | 27,498.70% | 1,066,200.00% | 40.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.51% | -107.05% | -143.00% | -431.96% | -2,175.00% |
| Cash from Financing | -96.17% | 1,678.55% | -27.86% | -20.66% | -49.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.30% | 96.96% | 28.76% | -75.65% | -165.82% |